Background & Objective
The “free market” policy for price setting in the US contrasts with the highly regulated markets of other developed countries where price is determined through defined processes like health technology assessment frameworks that generally support value-based pricing (VBP).
Both Republican and Democrat administrations have campaigned to lower prescription drug costs, including proposals to allow Medicare to negotiate drug prices, reimportation of drugs from Canada, and international reference pricing (IRP), whereby drug prices are tied to those set in foreign markets, among others.
While studies have examined the potential impact of broad reforms, few have assessed how certain proposed policies would compare to each other with regards to reducing drug prices in the US.
Research Details
Conference: ISPOR
Focus Topics: Value Based Pricing (VBP), International Reference Pricing (IRP), US Drug Pricing, Market Access
Resources: GPI proprietary data, Price & Market Access Specialists, Partners and external sources.
Complete the form to download the full report.
